BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25290810)

  • 21. Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen.
    González-Mira E; Nikolić S; García ML; Egea MA; Souto EB; Calpena AC
    J Pharm Sci; 2011 Jan; 100(1):242-51. PubMed ID: 20575052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation.
    Liu X; Zhang Z; Jiang Y; Hu Y; Wang Z; Liu J; Feng R; Zhang J; Huang G
    Drug Deliv; 2015 Feb; 22(2):223-9. PubMed ID: 24559497
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
    Neupane YR; Srivastava M; Ahmad N; Kumar N; Bhatnagar A; Kohli K
    Int J Pharm; 2014 Dec; 477(1-2):601-12. PubMed ID: 25445972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil.
    Rajinikanth PS; Chellian J
    Int J Nanomedicine; 2016; 11():5067-5077. PubMed ID: 27785014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation of Coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique.
    Chen S; Liu W; Wan J; Cheng X; Gu C; Zhou H; Chen S; Zhao X; Tang Y; Yang X
    Drug Dev Ind Pharm; 2013 Jan; 39(1):20-8. PubMed ID: 23116283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of ibuprofen-loaded nanostructured lipid carrier-based gels: characterization and investigation of in vitro and in vivo penetration through the skin.
    Sütő B; Berkó S; Kozma G; Kukovecz Á; Budai-Szűcs M; Erős G; Kemény L; Sztojkov-Ivanov A; Gáspár R; Csányi E
    Int J Nanomedicine; 2016; 11():1201-12. PubMed ID: 27099487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
    Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
    Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid nanocarriers for dermal delivery of lutein: preparation, characterization, stability and performance.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Jul; 414(1-2):267-75. PubMed ID: 21596122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
    Das S; Ng WK; Tan RB
    Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Podophyllotoxin-Loaded Nanostructured Lipid Carriers for Skin Targeting: In Vitro and In Vivo Studies.
    Zhao J; Piao X; Shi X; Si A; Zhang Y; Feng N
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27869698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: Effect of cyclodextrin complexation.
    Mennini N; Cirri M; Maestrelli F; Mura P
    Int J Pharm; 2016 Dec; 515(1-2):684-691. PubMed ID: 27825863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation And Evaluation Of Nanostructured Lipid Carriers (NLCs) Of 20(S)-Protopanaxadiol (PPD) By Box-Behnken Design.
    Kim MH; Kim KT; Sohn SY; Lee JY; Lee CH; Yang H; Lee BK; Lee KW; Kim DD
    Int J Nanomedicine; 2019; 14():8509-8520. PubMed ID: 31749618
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved antimalarial activity of caprol-based nanostructured lipid carriers encapsulating artemether-lumefantrine for oral administration.
    Akpa PA; Ugwuoke JA; Attama AA; Ugwu CN; Ezeibe EN; Momoh MA; Echezona AC; Kenechukwu FC
    Afr Health Sci; 2020 Dec; 20(4):1679-1697. PubMed ID: 34394228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and Evaluation of Astaxanthin as Nanostructure Lipid Carriers in Topical Delivery.
    Geng Q; Zhao Y; Wang L; Xu L; Chen X; Han J
    AAPS PharmSciTech; 2020 Nov; 21(8):318. PubMed ID: 33175290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced skin penetration of lidocaine through encapsulation into nanoethosomes and nanostructured lipid carriers: a comparative study.
    Babaei S; Ghanbarzadeh S; Adib ZM; Kouhsoltani M; Davaran S; Hamishehkar H
    Pharmazie; 2016 May; 71(5):247-51. PubMed ID: 27348967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo Antiplasmodial Activity of Curcumin-Loaded Nanostructured Lipid Carriers.
    Rashidzadeh H; Salimi M; Sadighian S; Rostamizadeh K; Ramazani A
    Curr Drug Deliv; 2019; 16(10):923-930. PubMed ID: 31663477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: in vitro vs. in vivo studies.
    Vitorino C; Almeida A; Sousa J; Lamarche I; Gobin P; Marchand S; Couet W; Olivier JC; Pais A
    Eur J Pharm Biopharm; 2014 Feb; 86(2):133-44. PubMed ID: 24333401
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Formulation and evaluation of transdermal nanogel for delivery of artemether.
    Nnamani PO; Ugwu AA; Nnadi OH; Kenechukwu FC; Ofokansi KC; Attama AA; Lehr CM
    Drug Deliv Transl Res; 2021 Aug; 11(4):1655-1674. PubMed ID: 33742415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical delivery of enoxaparin using nanostructured lipid carrier.
    Jain A; Mehra NK; Nahar M; Jain NK
    J Microencapsul; 2013; 30(7):709-15. PubMed ID: 23534492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
    Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
    Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.